http://www.drugdiscoverynews.com/index.php?newsarticle=5053
A few weeks after reporting a late-stage study failure for its Type 1 diabetes treatment GAD65, Diamyd Medical AB has reported that Johnson & Johnson s Ortho-McNeil-Janssen Pharmaceuticals division has bailed on the drug and handed rights for the drug back to Diamyd.
A few weeks after reporting a late-stage study failure for its Type 1 diabetes treatment GAD65, Diamyd Medical AB has reported that Johnson & Johnson s Ortho-McNeil-Janssen Pharmaceuticals division has bailed on the drug and handed rights for the drug back to Diamyd.
